Nicox SA (NXOA) Stock Price & Analysis

1 Followers

NXOA Stock Chart & Stats

€0.21-€0.02(-9.79%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 0.21 - EUR 0.21
52-Week Range: EUR 0.21 - EUR 0.48
Previous Close: EUR 0.24
Volume: N/A
Average Volume (3M): 14
Market Cap: EUR 28.47M
Enterprise Value: EUR 33.63M
Total Cash (Recent Filing): EUR 4.15M
Total Debt (Recent Filing): EUR 406.33K
Price to Earnings (P/E): 4.3
Beta: 1.00
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Nicox SA News

Nicox Narrows Loss, Extends Cash Runway as NCX 470 Nears Key Regulatory Milestones

Nicox SA ( ($FR:ALCOX) ) just unveiled an announcement. Nicox reported a sharp improvement in its first-half 2026 results, with revenue more than doubling to €3.5 million and net loss

1w agoNXOA 0RCQ

Nicox to Present Phase 3 NCX 470 Glaucoma Data at AAOpt 2026

The latest announcement is out from Nicox SA ( ($FR:ALCOX) ). Nicox plans to showcase key Phase 3 data on its investigational glaucoma therapy NCX 470 at the American Academy

1M agoNXOA 0RCQ

Nicox Gains China NDA Review Acceptance for Glaucoma Drug NCX 470

An announcement from Nicox SA ( ($FR:ALCOX) ) is now available. Nicox SA said China’s National Medical Products Administration has accepted for review the New Drug Application for NCX 470,

2M agoNXOA 0RCQ

Ram Selvaraju Reiterates Buy on Nicox, Maintains Unchanged €1 ($1) Price Target Amid Strong Cash Runway and NCX 470 FDA Progress

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Nicox SA. The associated price target remains the same with €1.00. Ram Selvaraju has given his Buy rating

2M agoNXOA 0RCQ

Nicox Extends Cash Runway as NCX 470 Nears Key Regulatory Milestones

Nicox SA ( ($FR:ALCOX) ) has provided an announcement. Nicox has strengthened its financial position, reporting estimated cash and cash equivalents of €8.4 million as of 31 August 2026, up

2M agoNXOA 0RCQ

Ram Selvaraju Reiterates Buy on Nicox, Citing NCX 470 Regulatory Momentum and Keeping Price Target Unchanged at $1

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with a price target of €1.00. Ram Selvaraju has given his Buy rating

2M agoNXOA 0RCQ

Nicox Gets 2027 FDA Decision Date for Glaucoma Drug NCX 470

An update from Nicox SA ( ($FR:ALCOX) ) is now available. Nicox SA said the U.S. Food and Drug Administration has accepted the New Drug Application for its glaucoma candidate

2M agoNXOA 0RCQ

Nicox Advances Global Glaucoma Strategy as Ocumension Files NCX 470 NDA in China

Nicox SA ( ($FR:ALCOX) ) just unveiled an announcement. Nicox’s Chinese partner Ocumension Therapeutics has submitted a New Drug Application to China’s National Medical Products Administration for NCX 470, a

3M agoNXOA 0RCQ

Buy Rating Reiterated on Nicox as NCX 470 Progress Supports Unchanged €1 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with a price target of €1.00. Ram Selvaraju has given his Buy rating

4M agoNXOA 0RCQ

Nicox: Strengthened Balance Sheet and De-Risked NCX 470 Pivotal Data Support Reiterated Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Nicox SA. The associated price target remains the same with €1.50. Ram Selvaraju has given his Buy rating

10M agoNXOA 0RCQ

NXOA FAQ

What was Nicox SA’s price range in the past 12 months?

Nicox SA lowest stock price was €0.21 and its highest was €0.48 in the past 12 months.

What is Nicox SA’s market cap?

Nicox SA’s market cap is €28.47M.

When is Nicox SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nicox SA’s earnings last quarter?

Nicox SA released its earnings results on Oct 30, 2026. The company reported -€0.005 earnings per share for the quarter, beating the consensus estimate of -€0.02 by €0.015.

Is Nicox SA overvalued?

According to Wall Street analysts Nicox SA’s price is currently Undervalued.

Does Nicox SA pay dividends?

Nicox SA does not currently pay dividends.

What is Nicox SA’s EPS estimate?

Nicox SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nicox SA have?

Nicox SA has 99,068,710 shares outstanding.

What happened to Nicox SA’s price movement after its last earnings report?

Nicox SA reported an EPS of -€0.005 in its last earnings report, beating expectations of -€0.02. Following the earnings report the stock price went up 5.957%.

Which hedge fund is a major shareholder of Nicox SA?

Currently, no hedge funds are holding shares in DE:NXOA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nicox SA

Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.

Nicox SA (NXOA) Earnings & Revenues

Historic Earnings Reports

NXOA Stock 12 Month Forecast

Average Price Target

€1.00▲(371.70% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High€1.00

Average€1.00

Low€1.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	2	5	15
Technical Analysis	2	5	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to DE:NXOA
Company	Price & Change	Follow
FR:SIGHTGenSight Biologics SA

Compare DE:NXOA Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NXOA Stock Chart & Stats

Nicox SA News

Nicox Narrows Loss, Extends Cash Runway as NCX 470 Nears Key Regulatory Milestones

Nicox to Present Phase 3 NCX 470 Glaucoma Data at AAOpt 2026

Nicox Gains China NDA Review Acceptance for Glaucoma Drug NCX 470

Ram Selvaraju Reiterates Buy on Nicox, Maintains Unchanged €1 ($1) Price Target Amid Strong Cash Runway and NCX 470 FDA Progress

Nicox Extends Cash Runway as NCX 470 Nears Key Regulatory Milestones

Ram Selvaraju Reiterates Buy on Nicox, Citing NCX 470 Regulatory Momentum and Keeping Price Target Unchanged at $1

Nicox Gets 2027 FDA Decision Date for Glaucoma Drug NCX 470

Nicox Advances Global Glaucoma Strategy as Ocumension Files NCX 470 NDA in China

Buy Rating Reiterated on Nicox as NCX 470 Progress Supports Unchanged €1 Price Target

Nicox: Strengthened Balance Sheet and De-Risked NCX 470 Pivotal Data Support Reiterated Buy Rating

NXOA FAQ

Company Description

Nicox SA

Nicox SA (NXOA) Earnings & Revenues

NXOA Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium